ArticleBMC veterinary research2026
Comparative pharmacokinetics of trimethoprim-sulfadiazine and trimethoprim-sulfamethoxazole in dogs.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPotentiated sulphonamides, combining trimethoprim (TMP) with a sulphonamide such as sulfadiazine (SDZ) or sulfamethoxazole (SMX), are widely used in canine medicine. The standard 1:5 dose ratio was initially designed to achieve a plasma concentration ratio of approximately 1:19 in humans, considered optimal for antibacterial synergy. However, species differences in pharmacokinetics may influence whether this ratio is achieved and maintained in dogs. Updated pharmacokinetic data based on modern analytical techniques and unbound (active) drug concentrations are lacking. This study aimed to characterise and compare the pharmacokinetics and plasma protein binding of TMP/SDZ and TMP/SMX in dogs.
methodsBeagle dogs were administered TMP/SDZ or TMP/SMX intravenously and orally in a crossover design. In addition, TMP was administered orally alone once. Plasma concentrations of TMP, SDZ and SMX were quantified using ultra-high performance liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS). Population pharmacokinetic analysis was performed using nonlinear mixed-effects modelling. Protein binding was determined by ultrafiltration, and free fractions were estimated using linear mixed-effects models.
resultsOral bioavailability was high for all compounds (93-97%). TMP exhibited substantially higher clearance (0.44 L/h/kg) and a shorter elimination half-life (4.2 h) than SDZ (0.05 L/h/kg; 7.6 h) and SMX (0.026 L/h/kg; 12.6 h). TMP also showed a markedly larger apparent volume of distribution (2.67 L/kg) compared to the sulphonamides (approximately 0.5 L/kg). Protein binding differed between compounds, with population mean free fractions of 0.50 for SDZ, 0.33 for SMX, and 0.43 for TMP. Following both intravenous and oral administration, the free sulphonamide-to-TMP concentration ratios were only close to the proposed 1:19 ratio during the first hours after dosing. Thereafter, the ratios progressively increased due to the more rapid elimination of TMP.
conclusionsTMP/SDZ and TMP/SMX display distinct pharmacokinetic profiles in dogs, particularly with respect to clearance, half-life and protein binding. The commonly used 1:5 dose ratio does not maintain a stable 1:19 free concentration ratio over a 12 h dosing interval. These findings provide clinically relevant pharmacokinetic data to support rational and species-specific use of potentiated sulphonamides in dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.